Lung Diseases Cies Search Engine [selected websites]


Blog Archive

Oct 3, 2008

Teva Pharmaceutical : Proair® HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication

September 24, 2008 - Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ProAir® HFA (albuterol sulfate) Inhalation Aerosol for use in patients as young as 4 years of age. Previously, ProAir HFA had been indicated for use in patients aged 12 and older.
In clinical studies, ProAir HFA, the market leading albuterol sulfate inhaler, exhibited significant bronchodilator efficacy in pediatric asthmatics aged 4 to 11 years. ProAir HFA provides physicians with a treatment option to help relieve children's asthma symptoms as they occur wherever they occur, which is especially important as children return to school. With asthma affecting more than one child in every 20 in the United States, studies show that asthma emergency room and hospitalization rates spike in September... Teva Pharmaceutical's Press Release -